Positives

• Rivastigmine transdermal patches are FDA-approved for cognitive impairment in Alzheimer’s and Parkinson’s dementia, with the patch route producing fewer GI side effects (nausea, vomiting) than the oral formulation — relevant for Long COVID patients with overlapping gastroparesis PubMed.
  
  

Negatives

• Even among dementia patients prescribed Exelon, only about a quarter rate themselves moderately or markedly improved, suggesting most users see little visible cognitive change on the patch Lewy Body Dementia Association.
• The patch frequently causes allergic contact dermatitis at the application site, and treatment is associated with nausea, vomiting, diarrhea, anorexia, and weight loss that can force discontinuation MedlinePlus.

Hurdles & Side Effects

• Atypical cutaneous reactions to the rivastigmine patch are documented and require rotation of application sites; chronic use can also produce cholinergic effects (bradycardia, increased GI motility, urinary frequency) that compound autonomic symptoms in Long COVID PubMed.
  
  
• Insurance authorization is essentially limited to Alzheimer’s and Parkinson’s dementia diagnoses; off-label Long COVID prescribing requires either a sympathetic neurologist or out-of-pocket payment of roughly $300-500/month Mayo Clinic.